Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 1NET 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 135Carcinoma, Hepatocellular 81Neoplasms 53Small Cell Lung Carcinoma 51Breast Neoplasms 50Lung Neoplasms 45Triple Negative Breast Neoplasms 41Colorectal Neoplasms 39Melanoma 38Carcinoma, Transitional Cell 37Urinary Bladder Neoplasms 33Neoplasm Metastasis 32Carcinoma, Renal Cell 30Ovarian Neoplasms 20Uterine Cervical Neoplasms 19Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Head and Neck Neoplasms 15Liver Neoplasms 14Prostatic Neoplasms 13Glioblastoma 12Solid Tumors 11Recurrence 11Sarcoma 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Lymphoma 9Kidney Neoplasms 9Endometrial Neoplasms 9Mesothelioma, Malignant 8

Interventions

Gemcitabine 61Cisplatin 39Oxaliplatin 31Capecitabine 29Fluorouracil 22Leucovorin 20Irinotecan 12pembrolizumab 11130-nm albumin-bound paclitaxel 10durvalumab 9Erlotinib Hydrochloride 8Trastuzumab 7Bevacizumab 7Taxes 6Platinum 6Magnetic Resonance Spectroscopy 6Biopsy 6Albumin-Bound Paclitaxel 61,2-diaminocyclohexaneplatinum II citrate 6Specimen Handling 5Sorafenib 5Radiotherapy 5Docetaxel 5Carboplatin 5Immunohistochemistry 4trifluridine tipiracil drug combination 3dehydroftorafur 3atezolizumab 3Watchful Waiting 3Tegafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × atezolizumab × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04941287 2025-05-23

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
57 enrolled 13 charts
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT03201458 2024-04-05

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

National Cancer Institute (NCI)

Phase 2 Completed
86 enrolled 16 charts
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡